High-Concentration KLK1 Formulation for Parenteral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly in managing blood glucose levels and insulin production, face challenges with inefficiencies and safety concerns in formulations and administration methods, especially for high-concentration tissue kallikrein-1 (KLK1) formulations which often require large volumes and have issues with aggregation and stability.
Innovation Solution
A high-concentration composition of human tissue kallikrein-1 (hKLK1) polypeptide with a pH of less than 5 and a sialic acid content of at least 4 moles per mole, formulated for parenteral administration, which is substantially free of aggregates and has improved pharmacokinetic and pharmacodynamic parameters, including increased bioavailability and prolonged absorption when administered subcutaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high-concentration KLK1 formulations are used, then treatment efficacy is improved, but aggregation and stability issues worsen
Solution Approach 1:
The patent modifies critical formulation parameters including pH (optimized to specific ranges), ionic strength, and excipient concentrations to stabilize high-concentration KLK1 formulations. These parameter changes prevent aggregation while maintaining therapeutic efficacy, directly resolving the contradiction between concentration and stability.
Solution Approach 2:
The formulation employs composite material strategies by combining KLK1 with specific excipients and stabilizers in defined ratios. This composite approach creates a synergistic system where the combination of components prevents aggregation better than individual components alone, enabling high concentration without sacrificing stability.
2Quantity of substance
If large volumes of KLK1 formulation are administered, then adequate dosing is achieved, but patient comfort and safety worsen
Solution Approach 1:
By optimizing the concentration parameter of the formulation, the patent enables delivery of adequate dosages in smaller volumes. This parameter change directly addresses the contradiction by increasing the amount of active substance per unit volume, thereby reducing total injection volume while maintaining therapeutic dosage.
3Ease of operation
If conventional formulations are used, then administration is simple, but bioavailability and absorption are insufficient
Solution Approach 1:
The patent optimizes formulation parameters such as pH, osmolarity, and excipient composition to enhance bioavailability and absorption characteristics. These parameter changes improve reliability of drug delivery without compromising the simplicity of administration, as the formulation remains suitable for standard injection routes.
Data Source
AI summary
Provided are high concentration compositions of tissue kallikrein-1 (KLK1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human KLK1 (rhKLK1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof.